FDA OKs Merck drug, 1st in new cancer drug class

(File) (Joe Raedle, Getty Images)
(File) (Joe Raedle, Getty Images)
Set Text Size SmallSet Text Size MediumSet Text Size LargeSet Text Size X-Large
Share
Updated: 9/04 12:54 pm

WHITEHOUSE STATION, N.J. (AP) — U.S. regulators have approved the first drug in a new class of cancer medicines that work by stimulating the immune system, a Merck drug developed for treating deadly skin cancer.

The Food and Drug Administration says it has granted accelerated approval to Merck's Keytruda, for treating melanoma that's spread or can't be surgically removed, in patients previously treated with another drug.

The drug, known chemically as pembrolizumab, is part of a hot, promising new class of antibody-based drugs that work by taking a brake off the immune system so it can better recognize and attack cancer cells.

Merck's drug is the first in the class approved in the U.S. Rival Bristol-Myers Squibb and a partner got a similar drug approved in Japan in July and are seeking U.S. approval.

 

©2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Share
NEWSCASTS ON DEMAND

What's On

All content © Copyright 2014 Intermountain West Communications Company. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.
You may also view our Sitemap

Inergize Digital This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.